CD79A Antibody (IGA/515) - Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody

Catalog Number	Mfr. No.	Quantity
NBP247839A	Novus Biologicals NBP2478390.1MG	0.1 mg
NBP247839B	Novus Biologicals NBP2478390.2MG	0.2 mg

Description

CD79A Monoclonal specifically detects CD79A in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence, CyTOF-ready.

Specifications

• Antigen: CD79A
• Concentration: 1.0 mg/mL
• Applications: Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence, CyTOF
• Conjugate: Unconjugated
• Host Species: Mouse
• Research Discipline: Adaptive Immunity, Cell Biology, Immunology
• Formulation: PBS with No Preservative
• Gene ID (Entrez): 973
• Immunogen: Recombinant full-length human IGA protein
• Primary or Secondary: Primary
• Content And Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Molecular Weight of Antigen: 44 kDa

• Clone: IGA/515
• Dilution: Flow Cytometry : 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin : 0.25 - 0.5 ug/ml, Immunofluorescence : 0.5 - 1.0 ug/ml, CyTOF-ready
• Classification: Monoclonal
• Form: Purified
• Regulatory Status: RUO
• Target Species: Human
• Gene Alias: CD79a antigen, CD79A antigen (immunoglobulin-associated alpha), CD79a molecule, immunoglobulin-associated alpha, IGAB-cell antigen receptor complex-associated protein alpha chain, Ig-alpha, MB1, MB-1, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein
• Gene Symbols: CD79A
• Isotype: IgG1 κ
• Purification Method: Protein A or G purified
• Test Specificity: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.